[go: up one dir, main page]

BRPI0814220B8 - purificação de fator viii usando uma resina multimodal ou de modo misto - Google Patents

purificação de fator viii usando uma resina multimodal ou de modo misto

Info

Publication number
BRPI0814220B8
BRPI0814220B8 BRPI0814220A BRPI0814220A BRPI0814220B8 BR PI0814220 B8 BRPI0814220 B8 BR PI0814220B8 BR PI0814220 A BRPI0814220 A BR PI0814220A BR PI0814220 A BRPI0814220 A BR PI0814220A BR PI0814220 B8 BRPI0814220 B8 BR PI0814220B8
Authority
BR
Brazil
Prior art keywords
multimodal
mixed
mode resin
factor viii
purification
Prior art date
Application number
BRPI0814220A
Other languages
English (en)
Inventor
Karlsson Johan
Thim Lars
Bang Susanne
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BRPI0814220A2 publication Critical patent/BRPI0814220A2/pt
Publication of BRPI0814220B1 publication Critical patent/BRPI0814220B1/pt
Publication of BRPI0814220B8 publication Critical patent/BRPI0814220B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

purificação de fator vlll usando uma resina multimodal ou de modo misto. a presente invenção refere-se a um método para purificação de uma proteína recombinante usando uma resina multimodal ou de modo misto contendo iigantes que incluem uma parte hidrofóbica e uma parte negativamente carregada é descrito. a invenção é vantajosa por ser um processo cromatográfico de etapa única que não requer ajuste de ph ou de condutividade durante a etapa de carregamento e resulta em um alto rendimento e potência. o processo é usado para a purificação de composições recombinantes de fator de coagulação, particularmente fator vlll recombinante.
BRPI0814220A 2007-07-11 2008-07-11 purificação de fator viii usando uma resina multimodal ou de modo misto BRPI0814220B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07112287.3 2007-07-11
EP07112287 2007-07-11
PCT/EP2008/059094 WO2009007451A1 (en) 2007-07-11 2008-07-11 Purification of factor viii using a mixed-mode or multimodal resin

Publications (3)

Publication Number Publication Date
BRPI0814220A2 BRPI0814220A2 (pt) 2015-01-06
BRPI0814220B1 BRPI0814220B1 (pt) 2019-09-17
BRPI0814220B8 true BRPI0814220B8 (pt) 2021-05-25

Family

ID=38472947

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814220A BRPI0814220B8 (pt) 2007-07-11 2008-07-11 purificação de fator viii usando uma resina multimodal ou de modo misto

Country Status (15)

Country Link
US (1) US8399620B2 (pt)
EP (1) EP2167526B1 (pt)
JP (1) JP5323072B2 (pt)
KR (1) KR101293504B1 (pt)
CN (1) CN101730707B (pt)
AT (1) ATE503763T1 (pt)
AU (1) AU2008274195B2 (pt)
BR (1) BRPI0814220B8 (pt)
CA (1) CA2692814A1 (pt)
DE (1) DE602008005885D1 (pt)
ES (1) ES2364118T3 (pt)
NL (1) NL300663I2 (pt)
PL (1) PL2167526T3 (pt)
RU (1) RU2493163C2 (pt)
WO (1) WO2009007451A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5619738B2 (ja) 2008-06-24 2014-11-05 オクタファルマ アクチェンゲゼルシャフト 凝固第viii因子の精製方法
US9120873B2 (en) 2008-08-21 2015-09-01 Octapharma Ag Recombinantly produced human factor VIII and IX
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
US8277649B2 (en) 2009-12-14 2012-10-02 General Electric Company Membranes and associated methods for purification of antibodies
AU2011220163B2 (en) * 2010-02-24 2015-05-28 Chiesi Farmaceutici S.P.A. Process for production and purification of recombinant lysosomal alpha-mannosidase
RU2731720C2 (ru) 2010-03-30 2020-09-08 Октафарма Аг Способ очистки витамин к-зависимых белков, таких как коагуляционный фактор vii
ES2596727T3 (es) 2010-03-30 2017-01-11 Octapharma Ag Procedimiento de purificación de un factor proteico de crecimiento G-CSF
CA2815282C (en) 2010-11-05 2019-05-21 F. Hoffmann-La Roche Ag Optimized method for antibody capturing by mixed mode chromatography
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
CN105777862A (zh) 2012-10-24 2016-07-20 建新公司 使用mes和mops作为流动相改性剂从多峰树脂洗脱生物分子
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
CN103396494B (zh) * 2013-04-27 2015-04-01 江苏省疾病预防控制中心 一种凝血因子ix的单克隆抗体
CA2911462C (en) 2013-05-06 2021-04-06 Sanofi Continuous multistep process for purifying antibodies
EP3160611A4 (en) * 2014-06-25 2018-02-28 JHL Biotech, Inc. Methods and reagents for purification of proteins
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第viii因子製剤
CN107406493B (zh) 2015-03-06 2021-08-13 康诺贝林伦瑙有限公司 具有改善的半衰期的经修饰的血管性血友病因子
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506113D0 (en) * 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
EP3205665A1 (en) * 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
GB201617240D0 (en) * 2016-10-11 2016-11-23 Profactor Pharma Ltd Purification process
US11299533B2 (en) 2017-06-23 2022-04-12 Takeda Pharmaceutical Company Limited Purification of factor VIII subspecies
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
AU2020300820A1 (en) 2019-07-04 2022-03-03 CSL Behring Lengnau AG A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302006D0 (sv) * 1992-10-02 1993-06-11 Kabi Pharmacia Ab Protein formulation
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE503424C2 (sv) 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
IL157309A0 (en) 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
BRPI0519626A2 (pt) * 2004-12-23 2009-02-25 Novo Nordisk Healthcare Ag mÉtodos para a reduÇço do teor de um ou mais contaminantes, do teor de proteÍna s em uma composiÇço, do teor de um ou mais contaminantes de proteÍna em um sobrenadante de cultura de cÉlula, do teor de proteÍna s em um sobrenadante de cultura de cÉlula, composiÇço compreendendo uma proteÍna dependente de vitamina k de interesse
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
JP5619738B2 (ja) 2008-06-24 2014-11-05 オクタファルマ アクチェンゲゼルシャフト 凝固第viii因子の精製方法

Also Published As

Publication number Publication date
CA2692814A1 (en) 2009-01-15
KR101293504B1 (ko) 2013-08-07
JP2010533150A (ja) 2010-10-21
WO2009007451A1 (en) 2009-01-15
EP2167526B1 (en) 2011-03-30
EP2167526A1 (en) 2010-03-31
ES2364118T9 (es) 2014-05-19
DE602008005885D1 (de) 2011-05-12
NL300663I2 (pt) 2016-09-22
BRPI0814220A2 (pt) 2015-01-06
US8399620B2 (en) 2013-03-19
ES2364118T3 (es) 2011-08-25
US20100204452A1 (en) 2010-08-12
CN101730707A (zh) 2010-06-09
RU2010103528A (ru) 2011-08-20
CN101730707B (zh) 2014-12-17
AU2008274195B2 (en) 2013-09-05
JP5323072B2 (ja) 2013-10-23
KR20100051620A (ko) 2010-05-17
PL2167526T3 (pl) 2011-09-30
AU2008274195A1 (en) 2009-01-15
BRPI0814220B1 (pt) 2019-09-17
RU2493163C2 (ru) 2013-09-20
ATE503763T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
BRPI0814220B8 (pt) purificação de fator viii usando uma resina multimodal ou de modo misto
BR112012004697A2 (pt) purificação melhorada de proteína através de uma eluição da proteína a modificada.
UA100901C2 (ru) Способ очищения фактора свертывания крови viii
BR112012024956A2 (pt) processo para a purificação de uma proteína de fator de crescimento
WO2008087184A3 (en) Process for the purification of fc-containing proteins
BRPI0919932A8 (pt) Pirrolina-carbóxi-lisina gerada biossinteticamente, bem como processo para preparar método para derivatizar uma proteína
BRPI0614761A2 (pt) proteìnas de fusão de albumina
BRPI0406576A (pt) Sìlicas altamente dispersìveis para aplicações de borracha
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
PE20150720A1 (es) Purificacion de iduronato-2-sulfatasa
ECSP088918A (es) Derivados de alcanos azabicíclicos sustituidos con bicicloheterociclos fusionados
EA200801531A1 (ru) Способы регулирования содержания маннозы в рекомбинантных белках
WO2008033413A3 (en) Albumin fusion proteins
TR201911082T4 (tr) K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem.
BRPI0921830A8 (pt) Composição para tratamento bucal compreendendo sílica fundida
BRPI0918670B8 (pt) anticorpo
BR112012009289A8 (pt) Método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)
BRPI0416544A (pt) proteìna de ligação de gag
BR112014015101A8 (pt) métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos
AU2014370873A1 (en) Method for purifying antibody having low isoelectric point
BR112021020204A2 (pt) Método para purificar anticorpo com região fc modificada
BRPI0417992A (pt) método para purificar fsh
BRPI0821467B8 (pt) composição de furina recombinante, método para produzir a composição de furina recombinante, e, método para produzir uma proteína madura utilizando a composição de furina recombinante
WO2008051178A3 (en) Purification of proteins with cationic surfactant
MY183011A (en) Novel purification process of gonadotropin

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2678 DE 03-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.